Adicet Bio Inc (ACET) Reports Q3 2022 Financial Results
Adicet Bio Inc (ACET) announced its financial results for the period ending Q3 2022.
Key Financial Highlights:
Revenue: 4814
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: 260642
targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable ACTIVE/1182
targeting CD20 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s lymphoma (NHL). •Presented positive preclinical data at the ISCT Annual Meeting. In May, Adicet announced data from a preclinical evaluation of ADI-001 at the ACTIVE/1182
targeting when compared to common gene-edited approaches. •Presented positive interim data from the Phase 1 study of ADI-001 at the 2022
📋 Adicet Bio, Inc. (ACET) - Financial Results
Filing Date: 2022-08-10
Accepted: 2022-08-10 07:05:30
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
Structured Data: